Show simple item record

dc.contributor.authorP, Piola
dc.contributor.authorC, Fogg
dc.contributor.authorF, Bajunirwe
dc.contributor.authorS, Biraro
dc.contributor.authorF, Grandesso
dc.contributor.authorE, Ruzagira
dc.contributor.authorJ, Babigumira
dc.contributor.authorI, Kigozi
dc.contributor.authorJ, Kiguli
dc.contributor.authorJ, Kyomuhendo
dc.contributor.authorL, Ferradini
dc.contributor.authorW R J R J, Taylor
dc.contributor.authorF, Checchi
dc.contributor.authorJ P, Guthmann
dc.date.accessioned2021-12-01T12:31:48Z
dc.date.available2021-12-01T12:31:48Z
dc.date.issued2005
dc.identifier.citationPiola, P., Fogg, C., Bajunirwe, F., Biraro, S., Grandesso, F., Ruzagira, E., ... & Guthmann, J. P. (2005). Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial. The Lancet, 365(9469), 1467-1473.en_US
dc.identifier.urihttp://ir.must.ac.ug/xmlui/handle/123456789/1056
dc.description.abstractBackground: The six-dose regimen of artemether-lumefantrine is effective and is among combination therapies prioritised to replace antimalarials that no longer work in Africa. However, its effectiveness has not been assessed in the field, and could be compromised by poor adherence, incorrect timing of doses, and insufficient intake of fatty foods with every dose. Our aim, therefore, was to assess the effectiveness of artemether-lumefantrine prescribed under routine outpatient conditions, compared with its efficacy when given under supervision to inpatients with acute uncomplicated falciparum malaria. Methods: We did a randomised trial to compare the efficacy, safety, and pharmacokinetics of artemetherlumefantrine. when given in a supervised (all doses observed with fatty-food intake; n=313) or unsupervised (first dose supervised followed by outpatient treatment with nutritional advice; n=644) setting to patients of all ages (weight _10 kg) with acute, uncomplicated falciparum malaria in Mbarara, Uganda. Our primary endpoint was 28-day, PCR-adjusted, parasitological cure rate. Analysis was by intention to treat and evaluability analysis. Findings: 38 patients were lost to follow-up and one withdrew consent. Day-28 cure rates were 97.7% (296 of 303) and 98.0% (603 of 615) in the supervised and unsupervised groups, respectively. We recorded 15 non-severe, drug-related adverse events, all of which resolved. Interpretation Artemether-lumefantrine has a high cure rate irrespective of whether given under supervision with food or under conditions of routine clinic practice. If used as first-line treatment, artemether-lumefantrine could make a substantial contribution to malaria control in Africa, though cost is an issue.en_US
dc.description.sponsorshipMédecins Sans Frontières.en_US
dc.language.isoen_USen_US
dc.publisherLanceten_US
dc.subjectArtemether-lumefantrineen_US
dc.subjectPlasmodium falciparumen_US
dc.subjectMalariaen_US
dc.subjectUgandaen_US
dc.titleSupervised versus unsupervised intake of sixdose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial.en_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

  • Research Articles [281]
    These are different research articles about different Scholars

Show simple item record